UNICHEMLABUnichem Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-27 (delayed ~30 min in market hours)
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in India, the United States, and internationally. The company offers formulation products that address various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management. It also offers active pharmaceutical ingredients, as well as contract manufacturing services. In addition, the company manufactures allopathic medicines, bulk drugs, and chemicals. It serves patients, distributors, health care professionals, and government institutions. The company was founded in 1944 and is based in Mumbai, India. Unichem Laboratories Limited is a subsidiary of Ipca Laboratories Limited.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on UNICHEMLAB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 34/100)
- • Revenue growth: -2.1% YoY
- • Profit growth: -79.3% YoY
- • RSI: 33
- • MACD: bearish
Bull case
- • Debt/Equity: 0.18
- • Promoter holding: 71.3%
- • Valuation vs sector: P/E 13.3 vs sector 36.2
- • Price vs SMA200: above
Bear case
- • Revenue growth: -2.1% YoY
- • Profit growth: -79.3% YoY
- • RSI: 33
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -2.1% YoY
- • Profit growth: -79.3% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹24.53). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.